This stock has never touched $5 during the last 12 months, as the company has made major strides in the Biotechnology & Drugs field during this period. It is therefore an outstanding stock investment opportunity. There are two strong business strategy planks on which investors can count for the road ahead.

The management has chosen the strategic collaboration route for the business end of its breakthrough technology. This approach gives the company the freedom to integrate vertically on its own, or to use the marketing and distribution systems of its associates. The latter includes some of the most established players in the pharmaceutical business. The stock has optimal opportunity to start generating revenues soon after final regulatory approvals.

The other strength of the stock is derived from the management’s selection of research projects. The core technology of disrupting genes has limitless applications. The company has kept financial parameters in full view by selecting Alzheimer’s, Irritable Bowel Syndrome, and Rheumatoid Arthritis for focus. All 10 candidate products under current development have excellent prospects of making it to markets, and they are all potential blockbusters.

The gene disruption process is set to revolutionize health care. It will allow the incurable and most painful conditions of today to be managed adequately for future quality of life and longevity. This stock is likely to emerge as the brightest prospect in the portfolios of investors who seek long term appreciation and reliable dividends. An illustrious Board of Directors and a highly skilled management appear set to take this company to great business heights.

Let us hear your thoughts below: